<DOC>
	<DOCNO>NCT02637167</DOCNO>
	<brief_summary>The objective trial study effect target gut microbiota patient heart failure ( HF ) . First , investigator characterize gut microbiota composition patient various degree systolic HF compare healthy control . Second , potential impact target gut microbiota improve HF investigated open label randomize control trial ( RCT ) probiotic , antibiotic control . The hypothesis test gut microbiota alter HF ; gut microbiota HF patient , interaction intestinal systemic innate immune system , contribute low-grade systemic inflammation well metabolic disturbance patient ; intervention probiotic non-absorbable antibiotic Rifaximin attenuate inflammatory metabolic disturbance improve heart function modulation gut microbiota .</brief_summary>
	<brief_title>GutHeart : Targeting Gut Microbiota Treat Heart Failure</brief_title>
	<detailed_description>While study inflammation heart failure ( HF ) focus down-stream mediator inflammation tissue damage , present study focus alteration gut microbiota potential upstream arm activation inflammatory response . The gut microbiota may play central role inflammatory arm pathogenesis HF , could also involve induction metabolic disturbance contribute progression disorder . Decompensated HF characterize decreased cardiac output congestion , contribute edema ischemia gut wall . Consequently , structural functional change occur , cause increase gut permeability . Several study show low grade leakage microbial product lipopolysaccharides ( LPS ) , occur across gut wall , potentially cause systemic inflammation activation Toll like receptor ( TLRs ) . Very small amount LPS show effectively induce release TNFα 6 , act cardiosuppressor via several pathway , include reduce mitochondrial activity , alter calcium homeostasis impair β-adrenergic signaling cardiomyocytes . Furthermore , investigator recently show microbiota-dependent marker TMAO associate clinical outcome chronic HF . Interestingly , gut decontamination antibiotic show reduce intestinal LPS-levels , monocyte expression LPS-receptor CD14 production TNFα . In addition , selective gut decontamination improve postoperative outcome cardiac surgery patient . However , present study fully characterize gut microbiota HF patient knowledge interaction gut microbiota , systemic inflammatory , metabolic disturbance myocardial dysfunction patient scarce . This project focus gut microbiota potential therapeutic target HF , open label randomize control trial ( RCT ) probiotic , antibiotic control , improve heart function primary end point .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Must least 18 year age , less 75 . Have heart failure New York Heart Association class II III Echocardiographically verify LVEF &lt; 40 % . On optimal treatment least 3 month Must lab value follow : Hemoglobin 10 g/l ; eGFR 30 ml/min ; ALT &lt; 150 units/l Signed informed consent expect cooperation patient treatment follow must obtain document accord ICH GCP , national/local regulation . Treatment antibiotic probiotic within last 12 week History hypersensitivity Rifaximin Rifamycin derive antimicrobial agent , component Xifaxan History hypersensitivity S. boulardii , yeast , component Precosa Polypharmacia increase risk interaction . i.e . patient extensive medication list ( e.g . 10 drug ) may influence patient safety compromise study result Malignancy cause , exclude basal cell carcinoma skin Acute coronary syndrome last 12 week Severely impaired kidney function ( i.e. , estimate glomerular filtration rate &lt; 30 ml/minute/1.73 m2 ) Impaired liver function ( Alanine aminotransferase &gt; 150 U/l ) decompensated liver cirrhosis classify ChildPugh B C. Ongoing infection , include GI infection Inflammatory bowel disease Bowel obstruction Active myocarditis , include Chagas disease Severe primary valvular heart disease Atrial fibrillation ventricular frequency &gt; 100/min Any , severe co morbid disease must expect severely reduce efficacy interventional product , survival compliance Treatment immunosuppressive drug Treatment rifamycins Rifaximin Central venous catheter Pregnancy plan pregnancy Nursing Poor compliance Any reason , opinion investigator , patient participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>inflammation</keyword>
	<keyword>rifaximin</keyword>
	<keyword>Saccharomyces boulardii</keyword>
	<keyword>gut microbiota</keyword>
</DOC>